[go: up one dir, main page]

CY1118930T1 - Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων - Google Patents

Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων

Info

Publication number
CY1118930T1
CY1118930T1 CY20171100583T CY171100583T CY1118930T1 CY 1118930 T1 CY1118930 T1 CY 1118930T1 CY 20171100583 T CY20171100583 T CY 20171100583T CY 171100583 T CY171100583 T CY 171100583T CY 1118930 T1 CY1118930 T1 CY 1118930T1
Authority
CY
Cyprus
Prior art keywords
methods
elastase proteins
reconstructioned
proteins
industrial construction
Prior art date
Application number
CY20171100583T
Other languages
English (en)
Inventor
F Nicholas Franano
Kimberly Bland
Marco D Wong
Bee C Ding
Original Assignee
Proteon Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Therapeutics, Inc. filed Critical Proteon Therapeutics, Inc.
Publication of CY1118930T1 publication Critical patent/CY1118930T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6448—Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21036—Pancreatic elastase (3.4.21.36)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Μέθοδοι για την βιομηχανική κατασκευή, καθαρισμό, συνταγοποίηση και χρήση βιολογικώς δραστικών ανασυνδυασμένων πρωτεϊνών ελαστάσης. Περιγράφονται μέθοδοι ανασυνδυασμού για παραγωγή θεραπευτικώς χρήσιμων πρωτεϊνών ελαστάσης, όπως είναι φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω πρωτεΐνες ελαστάσης. Επίσης αποκαλύπτονται νέες ανασυνδυασμένες πρωτεΐνες ελαστάσης και παρασκευάσματα πρωτεΐνης. Περιγράφονται μέθοδοι για θεραπεία και αποτροπή ασθενειών βιολογικών αγωγών χρησιμοποιώντας φαρμακευτικές συνθέσεις που περιέχουν τις πρωτεΐνες ελαστάσης της εφεύρεσης.
CY20171100583T 2007-12-04 2017-06-02 Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων CY1118930T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99231907P 2007-12-04 2007-12-04
US12/327,809 US8501449B2 (en) 2007-12-04 2008-12-03 Recombinant elastase proteins and methods of manufacturing and use thereof
EP08861467.2A EP2229440B9 (en) 2007-12-04 2008-12-04 Recombinant elastase proteins and methods of manufacturing and use thereof

Publications (1)

Publication Number Publication Date
CY1118930T1 true CY1118930T1 (el) 2018-01-10

Family

ID=40344763

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131101003T CY1114724T1 (el) 2007-12-04 2013-11-12 Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
CY20171100583T CY1118930T1 (el) 2007-12-04 2017-06-02 Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131101003T CY1114724T1 (el) 2007-12-04 2013-11-12 Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων

Country Status (25)

Country Link
US (14) US8501449B2 (el)
EP (3) EP3176262A1 (el)
JP (3) JP5829808B2 (el)
KR (3) KR20180011860A (el)
CN (4) CN101918547B (el)
AR (1) AR069584A1 (el)
AU (1) AU2008338743B2 (el)
BR (1) BRPI0819977A2 (el)
CA (1) CA2707051C (el)
CY (2) CY1114724T1 (el)
DK (2) DK2229440T3 (el)
ES (2) ES2627066T3 (el)
HR (2) HRP20131135T1 (el)
HU (1) HUE032739T2 (el)
IL (2) IL206157A (el)
LT (1) LT2666854T (el)
MX (2) MX2010006211A (el)
NZ (2) NZ601592A (el)
PL (2) PL2229440T3 (el)
PT (2) PT2666854T (el)
RS (2) RS55982B1 (el)
RU (1) RU2611200C2 (el)
SI (2) SI2229440T1 (el)
TW (2) TWI619726B (el)
WO (1) WO2009079220A2 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
CN102250863B (zh) * 2011-04-29 2012-12-05 天津金斯坦生物科技有限公司 基因重组人中性粒细胞弹性蛋白酶及其制备方法和该弹性蛋白酶的医药用途
US10202630B2 (en) 2013-03-15 2019-02-12 Alderbio Holdings Llc Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
JP6412552B2 (ja) 2013-03-15 2018-10-24 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 酵母及び他の形質転換細胞中のポリペプチドの高収率発現のための温度シフト
KR20250121449A (ko) * 2017-03-10 2025-08-12 볼트 쓰레즈, 인크. 재조합 단백질을 고분비 수율로 생산하기 위한 조성물 및 방법
WO2018232273A1 (en) * 2017-06-15 2018-12-20 The University Of Chicago Methods and compositions for treating cancer
AU2020394374A1 (en) * 2019-11-26 2022-06-02 Children's Hospital Medical Center CELA-1 inhibition for treatment of lung disease
US20230074785A1 (en) * 2020-01-14 2023-03-09 Basf Se Method For Producing Recombinant Protein In Yeast Cells
WO2022040288A1 (en) * 2020-08-18 2022-02-24 Onchilles Pharma, Inc. Modified serine protease proproteins
KR20230054355A (ko) * 2020-08-18 2023-04-24 온칠리스 파마 인코포레이티드 변형된 돼지 췌장 엘라스타아제 단백질

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2508408A (en) 1943-10-11 1950-05-23 Sidney H Liebson Averaging indicator
US2546308A (en) 1948-12-29 1951-03-27 Kahler John Floor marking device
US5212068A (en) * 1985-04-05 1993-05-18 Sankyo Company Limited Human pancreatic elastase
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
JPH0673456B2 (ja) 1986-04-26 1994-09-21 三共株式会社 ヒト・膵臓エラスタ−ゼ▲ｉ▼
US5162205A (en) 1986-04-26 1992-11-10 Sankyo Company, Limited Human pancreatic elastase I
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5543302A (en) 1988-05-27 1996-08-06 Solvay Enzymes, Inc. Proteases of altered stability to autolytic degradation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5503333A (en) 1993-06-23 1996-04-02 Laventure; David Duster extension tube system with dust collecting region and tube cleaner and method of using the same
DE69528614T2 (de) 1994-07-07 2003-06-18 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno, Delft Modifizierte Proenzyme als Substrate für proteolische Enzyme
US5955072A (en) 1994-07-13 1999-09-21 Sankyo Company, Limited Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
US7531325B2 (en) 1997-04-25 2009-05-12 Sembiosys Genetics Inc. Method for cleavage of fusion proteins
US20030207402A1 (en) 1997-08-22 2003-11-06 Erhard Kopetzki Autocatalytically activatable zymogenic precursors of proteases and their use
GB9817909D0 (en) 1998-08-17 1998-10-14 Zeneca Ltd DNA constructs
GB9908458D0 (en) 1999-04-13 1999-06-09 Queen Mary & Westfield College Enzyme
WO2000068363A2 (en) 1999-05-05 2000-11-16 Genentech, Inc. Elastase variants and substrates
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
DK2363142T3 (en) * 1999-09-24 2015-04-20 Proteon Therapeutics Inc Elastase for opening the closed biological channels
US7351549B2 (en) 2000-01-24 2008-04-01 Polymun Scientific Immunbiologische Forschung Gmbh Method for the manufacture of recombinant trypsin
WO2001062983A1 (en) 2000-02-24 2001-08-30 Phylos, Inc. Improved methods for generating catalytic proteins
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060189941A1 (en) 2002-01-22 2006-08-24 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
CA2517006A1 (en) 2003-02-20 2004-09-02 Proteon Therapeutics, Llc Methods for the treatment and prevention of diseases of biological conduits
US7571008B2 (en) 2003-08-18 2009-08-04 Medtronic, Inc. System and apparatus for remote activation of implantable medical devices
JP2008503712A (ja) * 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
CA2580957A1 (en) 2004-09-22 2006-04-06 Proteon Therapeutics, Inc. Methods for the treatment and prevention of diseases of biological conduits
RU2299070C2 (ru) * 2005-02-08 2007-05-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения заболевания вен и способ ее получения
US20060193824A1 (en) 2005-02-28 2006-08-31 Rubin Bruce K Methods for the treatment of infectious and inflammatory airway diseases
CN1769424A (zh) * 2005-09-20 2006-05-10 浙江大学 一种芽孢杆菌菌株及其用途
KR20140072201A (ko) * 2006-07-05 2014-06-12 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
DK2271767T3 (en) * 2008-04-03 2016-08-29 Cb Biotechnologies Inc Amplikonredning-multiplex polymerase chain reaction for the amplification of multiple target

Also Published As

Publication number Publication date
US20180155703A1 (en) 2018-06-07
US20180273928A1 (en) 2018-09-27
IL206157A (en) 2013-07-31
KR101732190B1 (ko) 2017-05-04
RS55982B1 (sr) 2017-09-29
US20180208918A1 (en) 2018-07-26
RS53083B (sr) 2014-06-30
US8501449B2 (en) 2013-08-06
RU2010127232A (ru) 2012-01-10
CN104711243A (zh) 2015-06-17
EP3176262A1 (en) 2017-06-07
CN101918547A (zh) 2010-12-15
CN101918547B (zh) 2015-01-14
US20150329846A1 (en) 2015-11-19
US9057060B2 (en) 2015-06-16
EP2229440B1 (en) 2013-08-28
US10301612B2 (en) 2019-05-28
HK1148772A1 (en) 2011-09-16
BRPI0819977A2 (pt) 2020-08-18
JP2015172056A (ja) 2015-10-01
PL2229440T3 (pl) 2014-07-31
US20160319267A1 (en) 2016-11-03
RU2611200C2 (ru) 2017-02-21
CN104711243B (zh) 2019-06-11
AU2008338743A1 (en) 2009-06-25
NZ585866A (en) 2012-09-28
EP2229440B9 (en) 2013-11-13
CA2707051A1 (en) 2009-06-25
JP2011505164A (ja) 2011-02-24
TWI619726B (zh) 2018-04-01
CN109893647A (zh) 2019-06-18
US20150166974A1 (en) 2015-06-18
ES2436783T3 (es) 2014-01-07
PT2229440E (pt) 2013-11-11
US20110008315A1 (en) 2011-01-13
US20190062718A1 (en) 2019-02-28
US20200208132A1 (en) 2020-07-02
SI2666854T1 (sl) 2017-06-30
IL226771A0 (en) 2013-07-31
TW200938219A (en) 2009-09-16
JP6084653B2 (ja) 2017-02-22
US20150322420A9 (en) 2015-11-12
EP2666854B1 (en) 2017-03-15
KR101824350B1 (ko) 2018-01-31
EP2666854A1 (en) 2013-11-27
MX2010006211A (es) 2010-10-25
HRP20170755T1 (hr) 2017-07-28
EP2229440A2 (en) 2010-09-22
DK2229440T3 (da) 2013-12-09
KR20180011860A (ko) 2018-02-02
PT2666854T (pt) 2017-06-28
TW201643188A (zh) 2016-12-16
JP2017104114A (ja) 2017-06-15
CA2707051C (en) 2019-05-21
US20090162343A1 (en) 2009-06-25
CY1114724T1 (el) 2016-10-05
WO2009079220A3 (en) 2009-08-06
US20160243205A1 (en) 2016-08-25
DK2666854T3 (da) 2017-05-22
US20110081705A1 (en) 2011-04-07
US10308924B2 (en) 2019-06-04
US20190010476A1 (en) 2019-01-10
HRP20131135T1 (hr) 2014-01-03
LT2666854T (lt) 2017-06-12
KR20100120639A (ko) 2010-11-16
HUE032739T2 (en) 2017-10-30
PL2666854T3 (pl) 2017-08-31
WO2009079220A2 (en) 2009-06-25
KR20160095184A (ko) 2016-08-10
CN103952388B (zh) 2017-10-03
MX341317B (es) 2016-08-15
TWI577385B (zh) 2017-04-11
US20130336956A1 (en) 2013-12-19
NZ601592A (en) 2014-02-28
CN103952388A (zh) 2014-07-30
AR069584A1 (es) 2010-02-03
IL206157A0 (en) 2010-12-30
SI2229440T1 (sl) 2013-12-31
ES2627066T3 (es) 2017-07-26
JP5829808B2 (ja) 2015-12-09
AU2008338743B2 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
CY1112682T1 (el) Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
BRPI0512286B8 (pt) proteínas quiméricas inibidoras da angiogênese e o uso
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
CY1121132T1 (el) ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
SE0301700D0 (sv) Novel compounds
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1114075T1 (el) Ενωσεις αλφα κετοαμιδιου ως αναστολεις πρωτεασης κυστεϊνης
MX2024005705A (es) Composiciones de liquidos ionicos.
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
CY1105008T1 (el) Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης
NO20055209D0 (no) Peptabody for cancerbehandling
UY30629A1 (es) Nuevo péptido de actinomadura namibiensis
CY1111048T1 (el) Ενωσεις που εμφανιζουν αντικαρκινικη δραστηριοτητα
DK1636261T3 (da) Thrombopoietinproteiner med forbedrede egenskaber